Skip to main content

05-07-2018 | Oncology | News | Article


Encorafenib–binimetinib approved for BRAF-mutated advanced melanoma

medwireNews: The US FDA has approved the use of encorafenib plus binimetinib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.

Following results from the COLUMBUS trial, the combination of the BRAF inhibitor encorafenib 45 mg once daily and the MEK inhibitor binimetinib 45 mg twice daily may now be used by patients whose mutations have been confirmed by an FDA-approved test.

Side effects associated with treatment include fatigue, gastrointestinal adverse events and arthralgia, with hemorrhage and headache cited as the most frequent reasons for treatment discontinuation.

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

See also:

Related topics

See the research in context now

with trial summaries, expert opinion and congress coverage